Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR), a biopharmaceutical company with a market capitalization of $2.68 billion ...

HC Wainwright reaffirmed their buy rating on shares of Arrowhead Pharmaceuticals (NASDAQ:ARWR – Free Report) in a research ...

Stock analysts at HC Wainwright dropped their FY2026 earnings per share (EPS) estimates for Arrowhead Pharmaceuticals in a research note issued on Thursday, January 23rd. HC Wainwright analyst P.

Arrowhead Pharmaceuticals Inc (ARWR) stock saw a decline, ending the day at $20.76 which represents a decrease of $-0.77 or -3.58% from the prior close of $21.53. The stock opened at $21.23 and ...

On the other hand, Arrowhead Pharmaceuticals has entered into a significant strategic partnership with Sarepta Therapeutics, involving a $500 million upfront payment and a $325 million equity ...

Arrowhead Pharmaceuticals Inc (ARWR) stock saw a modest uptick, ending the day at $21.53 which represents a slight increase of $1.82 or 9.23% from the prior close of $19.71. The stock opened at $20.05 ...

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR), a biopharmaceutical company with a market capitalization of $2.68 billion specializing in RNA interference (RNAi) technology, is on the cusp of a ...

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Abbott Laboratories (ABT – Research Report), ...

Guidewire Software Inc. (NYSE: GWRE) will replace Arrowhead Pharmaceuticals Inc. (NASD: ARWR) in the S&P MidCap 400, and Arrowhead Pharmaceuticals will replace Barnes Group Inc. (NYSE: B) in the S&P ...

Analyst Patrick Trucchio from H.C. Wainwright reiterated a Buy rating on Silence Therapeutics (SLN – Research Report) and keeping the price ...

(RTTNews) - S&P Dow Jones Indices said that Guidewire Software Inc. (GWRE) will replace Arrowhead Pharmaceuticals Inc. (ARWR) in the S&P MidCap 400, and Arrowhead Pharmaceuticals will replace ...